Crizotinib (Xalkori)

Targeted TherapyApproved for: NSCLCBiomarker: ALK, ROS1 Crizotinib (Xalkori) approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive or ROS1 positive and has metastasized (spread to other parts of the body). Related Research News Novel drug...
|
May 31, 2021
|

Entrectinib (Rozlytrek)

Targeted TherapyApproved for: NSCLCBiomarker: ROS1 Entrectinib (Rozlytrek) approved Targeted Therapy for non-small cell lung cancer (NSCLC) that is ROS1 positive. It is used in adults whose cancer has metastasized (spread to other parts of the body). Related Research News...
|
May 27, 2021
|